79 related articles for article (PubMed ID: 21304400)
1. Combined immunochemotherapy in selected patients with metastatic renal cell carcinoma: HLA class II genotype can help to predict response to therapy.
Bierer S; Hoffmeister I; Gerss J; Herrmann E; Wülfing C; Sibrowski W; Hertle L; Kelsch R
J Immunother; 2011 Mar; 34(2):196-201. PubMed ID: 21304400
[TBL] [Abstract][Full Text] [Related]
2. Heterozygosity or homozygosity for 2 HLA class II haplotypes predict favorable outcomes for renal cell carcinoma treated with cytokine therapy.
Ellerhorst JA; Hildebrand WH; Cavett JW; Fernandez-Vina MA; Hodges S; Poindexter N; Fischer H; Grimm EA
J Urol; 2003 Jun; 169(6):2084-8. PubMed ID: 12771724
[TBL] [Abstract][Full Text] [Related]
3. HLA class I (A, B, C) and class II (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China.
Trachtenberg E; Vinson M; Hayes E; Hsu YM; Houtchens K; Erlich H; Klitz W; Hsia Y; Hollenbach J
Tissue Antigens; 2007 Dec; 70(6):455-63. PubMed ID: 17900288
[TBL] [Abstract][Full Text] [Related]
4. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
5. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
6. Immunochemotherapy-associated protein patterns in tumour tissue and serum of patients with metastatic renal cell carcinoma.
Walter M; Heinze C; Steiner T; Pilchowski R; von Eggeling F; Wunderlich H; Junker K
Arch Physiol Biochem; 2010; 116(4-5):197-207. PubMed ID: 20836751
[TBL] [Abstract][Full Text] [Related]
7. HLA serological and class II genotyping in sarcoidosis patients in Japan.
Ishihara M; Ishida T; Inoko H; Ando H; Naruse T; Nose Y; Ohno S
Jpn J Ophthalmol; 1996; 40(1):86-94. PubMed ID: 8739505
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable.
Vogl UM; Zehetgruber H; Dominkus M; Hejna M; Zielinski CC; Haitel A; Schmidinger M
Br J Cancer; 2006 Sep; 95(6):691-8. PubMed ID: 16940978
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
Hong SK; Kwak C; Lee SE
Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
[TBL] [Abstract][Full Text] [Related]
11. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
12. Association of HLA class II genes with systemic sclerosis in Koreans.
Kang SH; Park MH; Song EY; Kang SJ; Lee EB; Song YW; Takeuchi F
J Rheumatol; 2001 Jul; 28(7):1577-83. PubMed ID: 11469465
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
Escudier B; Choueiri TK; Oudard S; Szczylik C; Négrier S; Ravaud A; Chevreau C; Venner P; Champagne P; Croteau D; Dupont E; Hariton C; Bukowski RM
J Urol; 2007 Nov; 178(5):1901-5. PubMed ID: 17868728
[TBL] [Abstract][Full Text] [Related]
14. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
[TBL] [Abstract][Full Text] [Related]
15. Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma.
Maruyama R; Yamana K; Itoi T; Hara N; Bilim V; Nishiyama T; Takahashi K; Tomita Y
Br J Cancer; 2006 Nov; 95(9):1244-9. PubMed ID: 17031406
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
[TBL] [Abstract][Full Text] [Related]
17. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
Zivadinov R; Uxa L; Bratina A; Bosco A; Srinivasaraghavan B; Minagar A; Ukmar M; Benedetto Sy; Zorzon M
Int Rev Neurobiol; 2007; 79():521-35. PubMed ID: 17531857
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
19. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?
Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297
[TBL] [Abstract][Full Text] [Related]
20. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
